Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia

• Published in: PloS one Vol. 10; no. 11; p. e0141706
• Main Authors: Fitzhugh, Courtney D., Hsieh, Matthew M., Allen, Darlene, Coles, Wynona A., Seamon, Cassie, Ring, Michael, Zhao, Xiongce, Minniti, Caterina P., Rodgers, Griffin P., Schechter, Alan N., Tisdale, John F., Taylor, James G.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 17.11.2015; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Adults; Age; Aged; Alkaline phosphatase; Anemia; Anemia, Sickle Cell - blood; Anemia, Sickle Cell - drug therapy; Anemia, Sickle Cell - mortality; Antisickling Agents - pharmacology; Antisickling Agents - therapeutic use; Cell survival; Creatinine; Damage tolerance; Echocardiography; Electronic medical records; Female; Fetal Hemoglobin - metabolism; Fetuses; Health hazards; Hematology; Hemoglobin; Hospitals; Humans; Hydroxyurea; Hydroxyurea - pharmacology; Hydroxyurea - therapeutic use; Laboratories; Male; Maximum Tolerated Dose; Medical electronics; Middle Aged; Mortality; Patients; Pediatrics; Proportional Hazards Models; Pulmonary hypertension; Regression analysis; Retrospective Studies; Sickle cell anemia; Sickle cell disease; Studies; Survival; Treatment Outcome; Young Adult

Adults with sickle cell anemia (HbSS) are inconsistently treated with hydroxyurea. We retrospectively evaluated the effects of elevating fetal hemoglobin with hydroxyurea on organ damage and survival in patients enrolled in our screening study between 2001 and 2010. An electronic medical record faci...